Implications of the HDAC6-ERK1 feed forward loop in immunotherapy

The oncogene HDAC6controls numerous cell processes that are related to tumorigenesis and metastasis, and has recently arisen as a target to treat malignancies. The ERK cascade is a classic pathway driving oncogenesis, and the components of this pathway are either highly mutated in cancers or are vital in cancer’s pathological activity. The interactions between these important components of tumor proliferation have been examined, and our research has demonstrated that they regulate each other as evidenced by different posttranslational modifications. Preclinical evidence also supports clinical trials cotargeting these two pathways, which may provide better efficacy than single treatment. Furthermore, HDAC6and ERK both participate in the regulation of T cell maturation and may have implications on the functions of immune cells. This leads to the possibility of connecting HDAC6and ERK to immunotherapy. In this review, we summarize the published studies about the interaction of HDAC6and ERK cascade and their relationship to cancers. We also include the association of HDAC6and ERK to immune system and discuss the plausibility of linking these to immunotherapy.